A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).Corey J. Langer, M. S. Berger, P Kovács et al.|Journal of Clinical Oncology|2011Cited by 19